Cadila Healthcare has received US Food and Drug Administration (USFDA) clearance for its Gujarat plant after an inspection. The USFDA inspected company’s Moraiya facility from February 6, 2017 to February 15, 2017. At the end of the inspection, no observation (483) has been issued.
Earlier, USFDA had issued a warning letter to the Cadila’s facility at Moraiya in Gujarat for breach of good manufacturing practices.
Cadila Healthcare is part of the Zydus Cadila Group. The company operates in areas of active pharmaceutical ingredients (API) to formulations, and animal health products to cosmeceuticals. Over the last five decades, it has been developing and manufacturing pharmaceutical products and selling and distributing these in over 50 countries around the world.
